GMT

Edison issues initiation on Cereno Scientific (CRNO B): Differentiated approach in CVD with potential

Retrieved on: 
Wednesday, March 13, 2024
Thomas Edison, HDAC, CVD, Risk, GMT, PAH, Thrombosis, Bleeding, Phase, Orthostatic hypertension, Probability, Valproate, Publication, Editorial, Partnership, Pharmaceutical industry

Cereno Scientific is a clinical-stage biotech, developing treatments for cardiovascular diseases (CVDs) using novel approaches.

Key Points: 
  • Cereno Scientific is a clinical-stage biotech, developing treatments for cardiovascular diseases (CVDs) using novel approaches.
  • Lead asset CS1, a delayed immediate release formulation of valproic acid, is an HDAC inhibitor, aiming to deliver disease-modifying results in pulmonary arterial hypertension (PAH).
  • Preclinical candidates include CS014, for thrombosis prevention without increased risk of bleeding (seen with current antithrombotics), and CS585 for CVD (specific indication not yet determined).
  • As with all Edison publications, Edison controls the editorial and timings of publications and we wish to make it clear that Cereno Scientific had no involvement in the aforementioned issue.

EQS-News: ESPG AG: Strong support for proposed resolutions to amended ESPG bond terms – next management call

Retrieved on: 
Wednesday, March 13, 2024
Federal Gazette, GMT, ESPG, Growth, Science, Person, LTV, Security (finance)

In discussions with diverse bondholders, the Management Board has so far received very positive feedback regarding the proposed suspension of the total LTV covenant as of 31 December 2023.

Key Points: 
  • In discussions with diverse bondholders, the Management Board has so far received very positive feedback regarding the proposed suspension of the total LTV covenant as of 31 December 2023.
  • Further details of the suggested process until the maturity of the bond in September 2026 will be published on the ESPG website in the next days.
  • Dr Ralf Nöcker, Management Board of ESPG AG, comments: "Following constructive discussions with bond investors, we expect a strong support for the suspension of the LTV covenant for the previous year, should this turn out to be necessary.
  • Together with our investors, we want to develop ESPG into the market leader for science park portfolios in Europe.”

EQS-News: Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024

Retrieved on: 
Wednesday, March 13, 2024
EDT, MorphoSys, GMT, Management, Q&A, Webcast, Conference

Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024

Key Points: 
  • Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024
    The issuer is solely responsible for the content of this announcement.
  • Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024
    MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the financial year 2023 on March 13, 2024, at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).
  • MorphoSys' Management team will host a conference call and webcast on March 14, 2024, at 01:00 pm CET (12:00 pm GMT; 08:00 am EDT) to present the results for the financial year 2023 and provide an outlook for 2024.
  • The conference call will start with a presentation by the Management team followed by a Q&A session.

EQS-News: ESPG bond: Registration period for vote ends on 15 March 2024 – Quorum not yet reached – Recommendation to accept the countermotion

Retrieved on: 
Wednesday, March 13, 2024
GMT, ESPG, Science, Exercise, LTV, Security (finance)

ESPG recommends all bondholders to vote in favour of the countermotion.

Key Points: 
  • ESPG recommends all bondholders to vote in favour of the countermotion.
  • The vote without a meeting will take place from 18 March to 20 March 2024.
  • Bondholders entitled to vote must register with the notary appointed by the company, Dr Johannes Beil, by the end of 15 March 2024 at the latest.
  • The countermotion – as well as correspondingly updated voting forms - can be accessed via the following link on the ESPG website: https://espg.space/investor_relations/corporate-bond-2018-2026/ .

Update on Shaikan Field local sales & Notice of 2023 Full Year Results

Retrieved on: 
Wednesday, March 13, 2024
GMT, GKP, Kurdistan Region, Gulf Keystone Petroleum

Gulf Keystone, a leading independent operator and producer in the Kurdistan Region of Iraq, is today providing an update on Shaikan Field local sales ahead of its 2023 Full Year Results on 21 March 2024.

Key Points: 
  • Gulf Keystone, a leading independent operator and producer in the Kurdistan Region of Iraq, is today providing an update on Shaikan Field local sales ahead of its 2023 Full Year Results on 21 March 2024.
  • The increase has brought gross average sales in 2024 year to date to c.29,600 bopd.
  • The Company continues to receive advance payments for its net entitlement of 36% of gross sales revenue.
  • The Company confirms it will be announcing its results for the full year ended 31 December 2023 on Thursday 21 March 2024.

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference

Retrieved on: 
Tuesday, March 5, 2024
GMT, Fireside, Fireside chats, Webcast, Conference

LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 at 11:20am ET / 03:20pm GMT.

Key Points: 
  • LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 at 11:20am ET / 03:20pm GMT.
  • A live audio webcast of the presentation can be accessed through the Investors section of the Company’s website at www.mereobiopharma.com/investors .
  • An archived replay of the webcast will be available on the Company’s website for two weeks following the live event.

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, February 29, 2024
Conference call, AstraZeneca, Research, New Drug Application, FDA, Quality of life, Marketing, EST, Growth, PDUFA, Travel, Conference, Chronic obstructive pulmonary disease, GMT, Hub, Safety, Information technology, Patient, Pharming, Clinical trial, Novartis, Disease, VRNA, IND, NDA, Head, Bromide, COPD, Pharmaceutical industry

LONDON and RALEIGH, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2023, and provides a corporate update.

Key Points: 
  • The debt facility provides non-dilutive capital and further financial flexibility to support Verona Pharma’s continued growth, including the commercialization of ensifentrine.
  • Net loss: Net loss was $14.1 million for the fourth quarter ended December 31, 2023 (Q4 2022: net loss $10.5 million).
  • Verona Pharma will host an investment community webcast and conference call at 9:00 a.m. EST / 2:00 p.m. GMT on Thursday, February 29, 2024, to discuss the fourth quarter and full year 2023 financial results and the corporate update.
  • An electronic copy of the fourth quarter and full year 2023 results press release will also be made available today on the Company’s website.

CompoSecure Chief Product and Innovation Officer to Speak on Digital Transformation for Financial Institutions at Finovate Europe 2024

Retrieved on: 
Tuesday, February 27, 2024
Digital transformation, AI, AMRO Bank, Lloyds Banking Group, Digital, GMT, Authentication, Fintech, ABM, ING

LONDON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- CompoSecure, Inc. (Nasdaq: CMPO), a leader in metal payment cards, security, and authentication solutions, today announced that Dr. Adam Lowe, Chief Product and Innovation Officer, will speak on a panel at Finovate Europe 2024 in London on February 28 at 9:40 am GMT.

Key Points: 
  • LONDON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- CompoSecure, Inc. (Nasdaq: CMPO), a leader in metal payment cards, security, and authentication solutions, today announced that Dr. Adam Lowe, Chief Product and Innovation Officer, will speak on a panel at Finovate Europe 2024 in London on February 28 at 9:40 am GMT.
  • Finovate brings together financial institutions, fintech startups and industry experts to explore the latest trends and innovations in the financial technology sector.
  • The panel, titled " Power Panel: Finding New Opportunities Through Digital Transformation ," will discuss innovative approaches and embedded solutions to digital payment security that will help financial institutions grow and future-proof their business without changing customer behavior.
  • "Digital transformation is the single most significant trend in banking being fueled by the dramatic rise in cybersecurity threats and growing demand for convenient and secure digital services,” said Lowe.

CMR Surgical hires industry leader to drive operations across Asia Pacific, the Middle East and Africa

Retrieved on: 
Monday, February 19, 2024
Hospital, CMR Surgical, Growth, Johnson & Johnson, Surgeon, GMT, CMR, Patient, Vice

CMR Surgical hires industry leader to drive operations across Asia Pacific, the Middle East and Africa

Key Points: 
  • CMR Surgical hires industry leader to drive operations across Asia Pacific, the Middle East and Africa
    Sushobhan Dasgupta joins as President and Chief Commercial Officer for Asia Pacific, the Middle East and Africa
    CAMBRIDGE, UK – 19 February 2024, 07:00 (GMT).
  • CMR Surgical (CMR or ‘the Company’), the global surgical robotics business, today announces that Sushobhan Dasgupta has joined the Company as President and Chief Commercial Officer for Asia Pacific, the Middle East and Africa.
  • Sushobhan brings over 30 years of global healthcare experience across diverse MedTech markets worldwide, including three decades with Johnson & Johnson (J&J).
  • Supratim Bose, Chief Executive Officer of CMR Surgical, commented: “Asia Pacific, the Middle East and Africa are some of the fastest growing markets in the world for surgical robotics and so we are pleased to welcome Sushobhan to CMR to oversee our commercial operations across these regions.

CMR Surgical hires industry leader to drive operations across Asia Pacific, the Middle East and Africa

Retrieved on: 
Monday, February 19, 2024
Hospital, CMR Surgical, Growth, Johnson & Johnson, Surgeon, GMT, CMR, Patient, Vice

CMR Surgical hires industry leader to drive operations across Asia Pacific, the Middle East and Africa

Key Points: 
  • CMR Surgical hires industry leader to drive operations across Asia Pacific, the Middle East and Africa
    Sushobhan Dasgupta joins as President and Chief Commercial Officer for Asia Pacific, the Middle East and Africa
    CAMBRIDGE, UK – 19 February 2024, 07:00 (GMT).
  • CMR Surgical (CMR or ‘the Company’), the global surgical robotics business, today announces that Sushobhan Dasgupta has joined the Company as President and Chief Commercial Officer for Asia Pacific, the Middle East and Africa.
  • Sushobhan brings over 30 years of global healthcare experience across diverse MedTech markets worldwide, including three decades with Johnson & Johnson (J&J).
  • Supratim Bose, Chief Executive Officer of CMR Surgical, commented: “Asia Pacific, the Middle East and Africa are some of the fastest growing markets in the world for surgical robotics and so we are pleased to welcome Sushobhan to CMR to oversee our commercial operations across these regions.